Table 3.

Associations of serum uromodulin with mortality, kidney failure, and major adverse cardiovascular events

OutcomeEventsHazard Ratio (95% CI)
UnivariableModel 1aModel 2bModel 3c
All-cause mortality
 HR per SD higher serum uromodulin335/51430.61 (0.52 to 0.71)0.67 (0.57 to 0.78)0.75 (0.63 to 0.89)0.80 (0.66 to 0.96)
 Quartile 1 (≤55.6 ng/ml)1 (reference)1 (reference)1 (reference)1 (reference)
 Quartile 2 (>55.6–83.4 ng/ml)0.63 (0.48 to 0.82)0.69 (0.52 to 0.90)0.76 (0.57 to 1.01)0.80 (0.60 to 1.07)
 Quartile 3 (>83.4–125.3 ng/ml)0.48 (0.36 to 0.65)0.53 (0.39 to 0.71)0.62 (0.45 to 0.86)0.70 (0.50 to 0.97)
 Quartile 4 (>125.3 ng/ml)0.31 (0.22 to 0.44)0.40 (0.28 to 0.57)0.50 (0.34 to 0.75)0.57 (0.38 to 0.87)
Kidney failure
 HR per SD higher serum uromodulin229/51430.30 (0.24 to 0.39)0.31 (0.25 to 0.40)0.61 (0.46 to 0.80)0.61 (0.46 to 0.81)
 Quartile 1 (≤55.6 ng/ml)1 (reference)1 (reference)1 (reference)1 (reference)
 Quartile 2 (>55.6–83.4 ng/ml)0.50 (0.37 to 0.68)0.50 (0.37 to 0.68)0.73 (0.53 to 0.99)0.73 (0.52 to 1.01)
 Quartile 3 (>83.4–125.3 ng/ml)0.27 (0.19 to 0.40)0.28 (0.19 to 0.42)0.64 (0.43 to 0.96)0.65 (0.43 to 0.99)
 Quartile 4 (>125.3 ng/ml)0.07 (0.03 to 0.14)0.06 (0.03 to 0.13)0.27 (0.12 to 0.59)0.24 (0.10 to 0.55)
MACE
 HR per SD higher serum uromodulin417/51430.68 (0.60 to 0.77)0.74 (0.65 to 0.84)0.80 (0.70 to 0.92)0.87 (0.77 to 1.02)
 Quartile 1 (≤55.6 ng/ml)1 (reference)1 (reference)1 (reference)1 (reference)
 Quartile 2 (>55.6–83.4 ng/ml)0.73 (0.57 to 0.93)0.75 (0.59 to 0.96)0.76 (0.59 to 0.99)0.85 (0.66 to 1.11)
 Quartile 3 (>83.4–125.3 ng/ml)0.61 (0.47 to 0.79)0.64 (0.49 to 0.83)0.70 (0.53 to 0.93)0.78 (0.58 to 1.03)
 Quartile 4 (>125.3 ng/ml)0.35 (0.26 to 0.48)0.43 (0.32 to 0.59)0.49 (0.35 to 0.69)0.63 (0.45 to 0.90)
  • MACE, major cardiovascular event—defined as a composite of fatal cardiovascular event, nonfatal myocardial infarction, nonfatal stroke, or incident peripheral vascular disease; HR, hazard ratio.

  • a Adjusted for age, sex, and body mass index.

  • b Model 1 plus eGFR and urinary albumin-creatinine ratio.

  • c Model 2 plus prevalent cardiovascular disease, diabetes and hypertension at baseline, systolic BP, diastolic BP, serum high and LDL concentration, serum C-reactive protein and phosphorus concentration, prescription of diuretics, and lipid- and BP-lowering medication.